---
title: "CJC-1295 / Ipamorelin"
slug: "cjc-1295-ipamorelin"
type: "compound"
category: "Longevity"
url: "https://peptidesciencethailand.com/compounds/cjc-1295-ipamorelin"
description: "Two peptides that work through complementary GH pathways: one initiates pulses, the other amplifies them. Includes dosing, safety data, and cycle guidance."
---
# CJC-1295 / Ipamorelin

*Synergistic Growth Hormone Optimization, Amplifying Natural GH Pulsatility*

**Category:** Longevity  
**Format:** Lyophilized Blend  
**Amount:** 5mg / 5mg  
**Purity:** >99.3% (HPLC)

## Overview

CJC-1295 and Ipamorelin represent a synergistic combination of two distinct peptide compounds that work through complementary mechanisms to optimize natural growth hormone secretion. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of GHRH, modified with a Drug Affinity Complex (DAC) that extends its half-life from minutes to approximately 6-8 days. Ipamorelin is a selective growth hormone secretagogue (GHS), a pentapeptide that mimics ghrelin's action at the GHS-R1a receptor in the pituitary gland.

The scientific rationale for combining these two peptides lies in their complementary mechanisms of action on growth hormone release. CJC-1295 acts as a GHRH analogue, binding to GHRH receptors on somatotroph cells in the anterior pituitary to amplify the natural GH-releasing signal. However, GHRH alone cannot initiate a GH pulse, it can only amplify existing pulsatile release patterns. Ipamorelin fills this gap by acting as a GHS receptor agonist, directly stimulating GH secretion through a ghrelin-mimetic pathway. When used together, CJC-1295 amplifies the magnitude of GH pulses that Ipamorelin initiates, resulting in significantly greater GH output than either compound alone.

What makes this combination particularly noteworthy in peptide research is its selectivity profile. Unlike other growth hormone secretagogues such as GHRP-6 or hexarelin, Ipamorelin does not significantly elevate cortisol, prolactin, or aldosterone levels, hormones whose elevation can produce unwanted side effects including water retention, appetite stimulation, and stress-related metabolic changes. Research published in the European Journal of Endocrinology confirmed Ipamorelin's highly selective GH-releasing properties, with dose-dependent GH elevation without corresponding increases in ACTH, cortisol, or prolactin.

CJC-1295 with DAC modification has been studied in clinical settings. A notable study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that single doses of CJC-1295 resulted in sustained GH elevation for up to 6 days, with 2-10 fold increases in mean GH concentrations and 1.5-3 fold increases in IGF-1 levels that persisted for 9-11 days. These sustained pharmacokinetics distinguish CJC-1295 from native GHRH, which has a plasma half-life of only 7-10 minutes.

The physiological implications of optimized GH pulsatility extend across multiple systems. Growth hormone influences body composition through enhanced lipolysis (fat breakdown) and protein synthesis (muscle maintenance). It supports collagen synthesis important for skin elasticity, joint integrity, and connective tissue health. GH also plays roles in bone mineral density maintenance, immune function modulation, cognitive performance, and sleep architecture, particularly deep slow-wave sleep, during which the largest natural GH pulses occur.

specialist supervision is critical for this combination because growth hormone pathways interact with numerous metabolic systems. Pre-existing conditions involving glucose metabolism, thyroid function, or previous history of certain proliferative conditions all require careful evaluation before initiating GH-optimizing protocols.

## Mechanism of Action

### Step 1: Ipamorelin Activates GHS-R1a Receptor

Ipamorelin binds to the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotroph cells, mimicking ghrelin's action to initiate a growth hormone release pulse without elevating cortisol or prolactin.

### Step 2: CJC-1295 Amplifies GHRH Signaling

CJC-1295 binds to GHRH receptors on the same somatotroph cells, amplifying the magnitude of the GH pulse initiated by Ipamorelin. The DAC modification extends its half-life to 6-8 days for sustained signaling.

### Step 3: Synergistic GH Pulse Release

The combined action produces GH pulses significantly larger than either compound alone, while maintaining the natural pulsatile pattern. This preserves the hypothalamic-pituitary feedback loop.

### Step 4: Hepatic IGF-1 Production

Elevated GH circulates to the liver, stimulating production of Insulin-like Growth Factor 1 (IGF-1), the primary mediator of growth hormone's anabolic, regenerative, and longevity-associated effects.

### Step 5: Multi-System Downstream Effects

IGF-1 and GH together promote lipolysis, protein synthesis, collagen production, bone mineral maintenance, improved sleep architecture, and enhanced immune function across multiple organ systems.

## Researched Benefits

### Enhanced Growth Hormone Output

The synergistic combination of CJC-1295 and Ipamorelin produces significantly greater GH pulses than either compound alone, with studies showing 2-10 fold increases in mean GH concentration while maintaining natural pulsatile release patterns and preserving hypothalamic feedback mechanisms.

### Selective Hormone Profile

Unlike other GH secretagogues, Ipamorelin does not significantly elevate cortisol, prolactin, or aldosterone. This selectivity means the growth hormone benefits come without the common side effects of other secretagogues including water retention, appetite stimulation, and stress hormone elevation.

### Body Composition Support

Optimized GH pulsatility supports enhanced lipolysis and protein synthesis, potentially improving the ratio of lean tissue to adipose tissue. Research indicates these effects on body composition work through both direct GH action and downstream IGF-1 mediated pathways.

### Recovery & Longevity Support

GH plays essential roles in collagen synthesis, bone mineral density, immune function, and sleep quality. Enhanced GH pulsatility may support joint integrity, connective tissue health, improved deep sleep architecture, and overall recovery capacity.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 100mcg CJC-1295 + 100mcg Ipamorelin, administered together subcutaneously twice daily (morning and before bed) |
| Route | Subcutaneous injection |
| Duration | 8-12 weeks per cycle |
| Cycle Notes | Protocols typically run 8-12 weeks followed by a 4-8 week rest period to prevent pituitary desensitization. Evening doses are often timed 30-60 minutes before sleep to coincide with natural nocturnal GH release. |
| Reconstitution | Reconstitute each peptide separately with bacteriostatic water. CJC-1295 at 5mg with 2.5mL yields 2000mcg/mL. Ipamorelin at 5mg with 2.5mL yields 2000mcg/mL. Store reconstituted solutions at 2-8°C. |

> **Specialist note:** Growth hormone optimization protocols require baseline blood work including IGF-1, fasting glucose, HbA1c, and thyroid panel. A specialist would assess whether GH-modulating compounds are appropriate based on metabolic profile and adjust dosing throughout the protocol.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder Blend |
| Amount | 5mg CJC-1295 + 5mg Ipamorelin per kit |
| Purity | >99.3% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | CJC-1295: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-DAC \| Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Molecular Weight | CJC-1295: 3647.28 g/mol \| Ipamorelin: 711.85 g/mol |
| Storage | Store lyophilized powder at -20°C. Reconstituted solution at 2-8°C. Protect from light. |
| Appearance | White lyophilized powder (separate vials) |

## Medical Guidance

CJC-1295/Ipamorelin combination directly modulates the growth hormone axis, which interacts with glucose metabolism, thyroid function, and insulin sensitivity. Pre-existing conditions affecting these systems, including diabetes, thyroid disorders, or history of certain proliferative conditions, require thorough specialist evaluation. Baseline and ongoing blood work monitoring IGF-1, glucose, and thyroid markers is essential throughout the protocol.

## Frequently Asked Questions

### Why are CJC-1295 and Ipamorelin used together?

CJC-1295 and Ipamorelin work through complementary mechanisms on growth hormone release. Ipamorelin initiates GH pulses by activating the GHS receptor (ghrelin pathway), while CJC-1295 amplifies those pulses by stimulating the GHRH receptor. Together, they produce significantly greater GH output than either alone, while maintaining the body's natural pulsatile release pattern and without elevating cortisol, prolactin, or aldosterone.

### What medical guidance applies to CJC-1295/Ipamorelin?

CJC-1295/Ipamorelin is a research-quality peptide combination that should only be used under qualified medical supervision. A doctor consultation ensures baseline blood work is performed, dosing is calibrated to individual hormone levels, and ongoing monitoring tracks your response. This is essential for safety, as GH-modulating compounds interact with glucose metabolism and thyroid function.

### What is the difference between CJC-1295 with and without DAC?

DAC (Drug Affinity Complex) is a modification that extends CJC-1295's half-life from approximately 30 minutes to 6-8 days by enabling it to bind to albumin in the bloodstream. CJC-1295 with DAC provides sustained GH elevation, while CJC-1295 without DAC (also called Mod GRF 1-29) produces more acute, shorter GH pulses. The choice between versions depends on the desired pharmacokinetic profile and is determined by a specialist.

### When should CJC-1295/Ipamorelin be administered?

Research protocols typically call for twice-daily subcutaneous injection, once in the morning on an empty stomach and once 30-60 minutes before bedtime. The evening dose is timed to coincide with the body's natural nocturnal growth hormone surge during deep sleep. Avoiding food 30 minutes before and after injection optimizes absorption, as elevated blood sugar can blunt GH release.

### What blood work is needed before starting CJC-1295/Ipamorelin?

A your specialist will typically order baseline IGF-1 levels, fasting glucose, HbA1c, complete thyroid panel (TSH, Free T3, Free T4), and comprehensive metabolic panel before initiating the protocol. Follow-up blood work at 4-6 week intervals monitors your response and ensures metabolic markers remain within healthy ranges throughout the cycle.

## Related Compounds

- /compounds/tesamorelin
- /compounds/mots-c
- /compounds/epithalon

## Comparisons

- /compare/cjc-1295-ipamorelin-vs-tesamorelin